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Background: Information from imaging techniques is determinant for suc-
cessful transcatheter aortic valve implantation (TAVI). The feasibility and utility
of Intra-aortic ultrasound (IAUS) to provide complementary information on top of
angiography and trans-oesophageal echocardiography have never been reported.
Methods: In consecutive patients undergoing TAVI in a single university
centre, IAUS was performed before and after balloon angioplasty and after TAVI.
We assessed off-line the dimensions of the aortic annulus, the extent of calcifica-
tion and localisation in relation to the coronary ostia, the quality of valve deploy-
ment and positioning, and compared to angiographic and intra-oesophageal data.
Results: 14 patients underwent TAVI with IAUS; 6 apical and 8 femoral
approach. IAUS was feasible in all patients. On average, each IAUS run lasted 90
seconds. No complications were observed related to IAUS. All 23 runs were suitable
for analysis; 4 baseline, 8 after balloon, 11 after TAVI. Relevant information pro-
vided by IAUS pre-procedure included annulus diameter, presence of extensive
calcifications and their position close to a coronary ostium. Post-balloon, IAUS made
it possible to assess sigmoid mobility. After TAVI, the diameter, area and symmetry
of the prosthesis could be measured and in 1 patient who had had balloon post-
dilatation for aortic insufficiency, an increase in stent was visible by IAUS.
Conclusion: IAUS appears to be safe and feasible during TAVI and provides
additional information on top of angiography and echography. The clinical value
of the incremental information provided by IAUS remains to be determined.
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Background: Transcatheter aortic valve implantation (TAVI) is performed
in a number of pts with a Log ES<20% due to comorbidities not included in
the calculation of the Log ES but increasing the risk of AVR. The TAVI
results in this sugroup of “lower risk” patients needed to be assessed.
Population and Methods: We retrospectively analysed 177 consecutive
Edwards balloon expandable TAVI patients included between May 2006 and
January 2011 in our center, and compared the clinical characeristics and
results at 30 days and 1 year of two groups according to the Log.ES<20%
(Low risk: LR): n=60 (34%), or 20% (High risk: HR): n=117 (66%). The
transfemoral approach was used in 128 (72.3%).
Results:
Mean Log ES was 11.9±4.9% and 32.2 ±10.3% in the LR and HR groups
respectively. Mediastinal radiotherapy (20%) and porcelain aorta (15%) were
the dominant inclusion factors in the LS group. Patients in the LR group were
younger (80±9 vs 84±5 years, p = 0.003), more often female (70% vs 43.6%,
p = 0.001), with previous stroke (3.3% vs 17.9%, p=0.004) or CABG (5% vs
33.3%, p<0.001). There was no significant difference in NYHA class, pres-
ence of chronic respiratory failure, diabetes, or pre-existent conductive disor-
ders. Procedural success was 100% vs 95.3% (p=0.1) in the LR and HR group
respectively. There was no significant difference in major vascular complica-
tions (5 vs 6%), major acute stroke (3.7 vs 4.4%), permanent pace maker (5
vs 6%) but less AKI class  2 (0% vs 6%, p=0.003) or life-threatening
bleeding (5% vs 19.7%, p=0.03) in the LR vs HR groups and a better safety
end point (6.8% vs 18.6%, p=0.02) and survival at 30-day (0% vs 11.1%,
p<0.04) and 1 year (5 vs 24.8%, p<0.01) in the LR group.
Conclusions: In patients with contra-indication to surgery but low Log ES
(<20%), TAVI is associated with similarly good procedural success and better
safety end point and mortality rates at 30-Day (0%) and 1 year (5%) than in
the regular high risk population.
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Purpose: Lipoprotein-associated phospholipase A2 (Lp-PLA2) predict cardio-
vascular events in patients with coronary artery disease (CAD) and heart
failure (HF) independently of traditional cardiovascular risk factors. Aims of
our study were (1) to assess relationships between Lp-PLA2 levels, cardiac
disease and treatments; (2) to evaluate the association of Lp-PLA2 level with
the severity of CAD and the extracoronary atherosclerosis.
Methods: 494 subjects (69.8% men, 64.2±16.7y) were recruited from a
population scheduled for diagnostic coronary angiography. Lp-PLA2 mass
concentration was assessed in serum with a Plac® – test turbidimetric immu-
noassay. Control Lp-PLA2 values were obtained in 61 healthy subjects (age
44.5±17.6y) without cardiovascular risk factors or cardiac treatment.
Results: In controls, mean Lp-PLA2 was 163±43 μg/L (men: 166±45 μg/L;
women:159±39 μg/L).
Survival in LR and HR groups
